Zealand Pharma A/S (OTCMKTS:ZLDPF) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) from a hold rating to a strong sell rating in a research report released on Thursday morning,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Finally, Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $52.68 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The stock’s 50-day moving average is $45.69 and its two-hundred day moving average is $49.49. The firm has a market cap of $3.77 billion, a P/E ratio of 8.74 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, August 13th. The company reported $8.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $8.47. The company had revenue of $698.62 million during the quarter, compared to the consensus estimate of $692.12 million. Zealand Pharma A/S had a return on equity of 18.53% and a net margin of 58.86%. Analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.